- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT04310007
Test dell'aggiunta della pillola chemioterapica, Cabozantinib, alla terapia immunitaria standard Nivolumab rispetto alla chemioterapia standard per il carcinoma polmonare non a piccole cellule
Uno studio randomizzato di fase II su cabozantinib e cabozantinib più nivolumab rispetto alla chemioterapia standard in pazienti con NSCLC non squamoso trattato in precedenza
This phase II trial compares cabozantinib alone and the combination of cabozantinib and nivolumab to standard chemotherapy in the treatment of patients with non-squamous non-small cell lung cancer (NSCLC). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ramucirumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as docetaxel, gemcitabine hydrochloride, paclitaxel, and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving cabozantinib alone or in combination with nivolumab may be more effective than standard chemotherapy in treating patients with non-small cell lung cancer.
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
PRIMARY OBJECTIVE:
I. To determine whether cabozantinib alone, or the combination of nivolumab and cabozantinib, as compared to standard chemotherapy alone, extends progression-free survival (PFS) for this patient population with non squamous NSCLC.
SECONDARY OBJECTIVES:
I. To determine the overall survival for each arm of the trial. II. To evaluate the best overall radiographic response rate for each arm of the trial.
III. To evaluate and describe the toxicity profile of monotherapy with cabozantinib, and the combination of nivolumab and cabozantinib in this patient population with non-squamous NSCLC.
EXPLORATORY IMAGING OBJECTIVES:
I. To describe time point tumor response assessment, overall best response, progression-free survival and overall survival using the conventional Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria and the exploratory revised CHOI criteria with all measurements performed by the central review.
II. To compare the progression-free survival using the RECIST1.1 imaging response assessment measurements by site study personnel to those performed by central review.
EXPLORATORY CORRELATIVE OBJECTIVE:
I. To perform correlative biomarker research on tissue and blood biospecimens collected within this trial.
OUTLINE:
STEP 1: Patients are randomized to 1 of 3 arms.
ARM A: Patients receive cabozantinib S-malate orally (PO) once daily (QD). Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may continue to receive therapy after investigator-assessed RECIST 1.1 defined progression, including stable clinical and performance status and have potential for continued clinical benefit.
ARM B: Patients receive cabozantinib S-malate PO QD and nivolumab intravenously (IV) over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may continue to receive therapy after investigator-assessed RECIST 1.1 defined progression, including stable clinical and performance status and have potential for continued clinical benefit.
ARM C: Patients receive ramucirumab IV over 30-60 minutes and docetaxel IV over 1 hour on day 1, or docetaxel IV over 1 hour on days 1 and 8, or gemcitabine hydrochloride IV on days 1 and 8, or paclitaxel IV over 3 hours on day 1, or nab-paclitaxel IV over 30 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity and at the discretion of the treating physician.
STEP 2: Patients in Arm C experiencing disease progression are assigned to Arm Z.
ARM Z: Patients receive cabozantinib S-malate PO QD and nivolumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may continue to receive therapy after investigator-assessed RECIST 1.1 defined progression, including stable clinical and performance status and have potential for continued clinical benefit.
Patients in all arms undergo echocardiogram (ECHO) as clinically indicated, computed tomography (CT) throughout the trial, and collection of blood on study.
After the completion of study treatment, patients are followed up every 3 months for up to 3 years.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
Alabama
-
Birmingham, Alabama, Stati Uniti, 35233
- Veterans Administration Medical Center - Birmingham
-
-
Alaska
-
Anchorage, Alaska, Stati Uniti, 98508
- Anchorage Associates in Radiation Medicine
-
Anchorage, Alaska, Stati Uniti, 99508
- Alaska Breast Care and Surgery LLC
-
Anchorage, Alaska, Stati Uniti, 99508
- Alaska Oncology and Hematology LLC
-
Anchorage, Alaska, Stati Uniti, 99508
- Alaska Women's Cancer Care
-
Anchorage, Alaska, Stati Uniti, 99508
- Anchorage Oncology Centre
-
Anchorage, Alaska, Stati Uniti, 99508
- Katmai Oncology Group
-
Anchorage, Alaska, Stati Uniti, 99508
- Providence Alaska Medical Center
-
Anchorage, Alaska, Stati Uniti, 99504
- Anchorage Radiation Therapy Center
-
Fairbanks, Alaska, Stati Uniti, 99701
- Fairbanks Memorial Hospital
-
-
Arizona
-
Goodyear, Arizona, Stati Uniti, 85338
- CTCA at Western Regional Medical Center
-
Kingman, Arizona, Stati Uniti, 86401
- Kingman Regional Medical Center
-
Phoenix, Arizona, Stati Uniti, 85004
- Cancer Center at Saint Joseph's
-
Tucson, Arizona, Stati Uniti, 85719
- Banner University Medical Center - Tucson
-
Tucson, Arizona, Stati Uniti, 85719
- University of Arizona Cancer Center-North Campus
-
-
Arkansas
-
Fort Smith, Arkansas, Stati Uniti, 72903
- Mercy Hospital Fort Smith
-
Hot Springs, Arkansas, Stati Uniti, 71913
- CHI Saint Vincent Cancer Center Hot Springs
-
-
California
-
Arroyo Grande, California, Stati Uniti, 93420
- PCR Oncology
-
Arroyo Grande, California, Stati Uniti, 93420
- Mission Hope Medical Oncology - Arroyo Grande
-
Burbank, California, Stati Uniti, 91505
- Providence Saint Joseph Medical Center/Disney Family Cancer Center
-
Carmichael, California, Stati Uniti, 95608
- Mercy San Juan Medical Center
-
Carmichael, California, Stati Uniti, 95608
- Mercy Cancer Center - Carmichael
-
Elk Grove, California, Stati Uniti, 95758
- Mercy Cancer Center - Elk Grove
-
Fremont, California, Stati Uniti, 94538
- Washington Health
-
Marysville, California, Stati Uniti, 95901
- Fremont - Rideout Cancer Center
-
Orange, California, Stati Uniti, 92868
- Saint Joseph Hospital - Orange
-
Palo Alto, California, Stati Uniti, 94304
- Stanford Cancer Institute Palo Alto
-
Rocklin, California, Stati Uniti, 95765
- Mercy Cancer Center - Rocklin
-
Sacramento, California, Stati Uniti, 95817
- University of California Davis Comprehensive Cancer Center
-
Sacramento, California, Stati Uniti, 95816
- Mercy Cancer Center - Sacramento
-
San Luis Obispo, California, Stati Uniti, 93401
- Pacific Central Coast Health Center-San Luis Obispo
-
Santa Maria, California, Stati Uniti, 93444
- Mission Hope Medical Oncology - Santa Maria
-
Woodland, California, Stati Uniti, 95695
- Woodland Memorial Hospital
-
-
Colorado
-
Aurora, Colorado, Stati Uniti, 80012
- Rocky Mountain Cancer Centers-Aurora
-
Aurora, Colorado, Stati Uniti, 80012
- The Medical Center of Aurora
-
Boulder, Colorado, Stati Uniti, 80303
- Boulder Community Foothills Hospital
-
Boulder, Colorado, Stati Uniti, 80304
- Rocky Mountain Cancer Centers-Boulder
-
Centennial, Colorado, Stati Uniti, 80112
- Rocky Mountain Cancer Centers - Centennial
-
Colorado Springs, Colorado, Stati Uniti, 80907
- Penrose-Saint Francis Healthcare
-
Colorado Springs, Colorado, Stati Uniti, 80907
- Rocky Mountain Cancer Centers-Penrose
-
Colorado Springs, Colorado, Stati Uniti, 80923
- Saint Francis Cancer Center
-
Denver, Colorado, Stati Uniti, 80218
- Presbyterian - Saint Lukes Medical Center - Health One
-
Denver, Colorado, Stati Uniti, 80220
- Rose Medical Center
-
Denver, Colorado, Stati Uniti, 80218
- Rocky Mountain Cancer Centers-Midtown
-
Denver, Colorado, Stati Uniti, 80220
- Rocky Mountain Cancer Centers-Rose
-
Denver, Colorado, Stati Uniti, 80218
- Colorado Blood Cancer Institute
-
Denver, Colorado, Stati Uniti, 80204
- Cancer Center of Colorado at Sloan's Lake
-
Denver, Colorado, Stati Uniti, 80209
- The Women's Imaging Center
-
Denver, Colorado, Stati Uniti, 80206
- National Jewish Health-Main Campus
-
Denver, Colorado, Stati Uniti, 80220
- Western Surgical Care
-
Denver, Colorado, Stati Uniti, 80218
- Saint Joseph Hospital - Cancer Centers of Colorado
-
Denver, Colorado, Stati Uniti, 80210
- AdventHealth Porter
-
Durango, Colorado, Stati Uniti, 81301
- Mercy Medical Center
-
Durango, Colorado, Stati Uniti, 81301
- CommonSpirit Cancer Center Mercy
-
Englewood, Colorado, Stati Uniti, 80113
- Mountain Blue Cancer Care Center - Swedish
-
Englewood, Colorado, Stati Uniti, 80113
- Swedish Medical Center
-
Englewood, Colorado, Stati Uniti, 80113
- Rocky Mountain Cancer Centers - Swedish
-
Englewood, Colorado, Stati Uniti, 80113
- The Melanoma and Skin Cancer Institute
-
Fort Collins, Colorado, Stati Uniti, 80524
- Poudre Valley Hospital
-
Fort Collins, Colorado, Stati Uniti, 80528
- Cancer Care and Hematology-Fort Collins
-
Golden, Colorado, Stati Uniti, 80401
- National Jewish Health-Western Hematology Oncology
-
Grand Junction, Colorado, Stati Uniti, 81501
- Saint Mary's Hospital and Regional Medical Center
-
Greeley, Colorado, Stati Uniti, 80631
- UCHealth Greeley Hospital
-
Greeley, Colorado, Stati Uniti, 80631
- Banner North Colorado Medical Center
-
Highlands Ranch, Colorado, Stati Uniti, 80129
- UCHealth Highlands Ranch Hospital
-
Lafayette, Colorado, Stati Uniti, 80026
- Good Samaritan Hospital - Cancer Centers of Colorado
-
Lakewood, Colorado, Stati Uniti, 80228
- Rocky Mountain Cancer Centers-Lakewood
-
Lakewood, Colorado, Stati Uniti, 80228
- CommonSpirit Saint Anthony Hospital Cancer Center
-
Littleton, Colorado, Stati Uniti, 80120
- Rocky Mountain Cancer Centers-Littleton
-
Littleton, Colorado, Stati Uniti, 80122
- AdventHealth Littleton
-
Lone Tree, Colorado, Stati Uniti, 80124
- Sky Ridge Medical Center
-
Lone Tree, Colorado, Stati Uniti, 80124
- Rocky Mountain Cancer Centers-Sky Ridge
-
Longmont, Colorado, Stati Uniti, 80501
- Longmont United Hospital
-
Longmont, Colorado, Stati Uniti, 80501
- Rocky Mountain Cancer Centers-Longmont
-
Loveland, Colorado, Stati Uniti, 80538
- Medical Center of the Rockies
-
Loveland, Colorado, Stati Uniti, 80539
- Banner North Colorado Medical Center - Loveland Campus
-
Parker, Colorado, Stati Uniti, 80138
- AdventHealth Parker
-
Pueblo, Colorado, Stati Uniti, 81004
- Saint Mary Corwin Medical Center
-
Thornton, Colorado, Stati Uniti, 80260
- Rocky Mountain Cancer Centers-Thornton
-
Thornton, Colorado, Stati Uniti, 80260
- National Jewish Health-Northern Hematology Oncology
-
-
Connecticut
-
West Haven, Connecticut, Stati Uniti, 06516
- Veterans Affairs Connecticut Healthcare System-West Haven Campus
-
-
Florida
-
Aventura, Florida, Stati Uniti, 33180
- Mount Sinai Comprehensive Cancer Center at Aventura
-
Fort Lauderdale, Florida, Stati Uniti, 33308
- Holy Cross Hospital
-
Miami Beach, Florida, Stati Uniti, 33140
- Mount Sinai Medical Center
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30308
- Emory University Hospital Midtown
-
Atlanta, Georgia, Stati Uniti, 30322
- Emory University Hospital/Winship Cancer Institute
-
Savannah, Georgia, Stati Uniti, 31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
-
Idaho
-
Boise, Idaho, Stati Uniti, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
Boise, Idaho, Stati Uniti, 83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell, Idaho, Stati Uniti, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Coeur d'Alene, Idaho, Stati Uniti, 83814
- Kootenai Health - Coeur d'Alene
-
Emmett, Idaho, Stati Uniti, 83617
- Walter Knox Memorial Hospital
-
Fruitland, Idaho, Stati Uniti, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Stati Uniti, 83642
- Idaho Urologic Institute-Meridian
-
Meridian, Idaho, Stati Uniti, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Stati Uniti, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa, Idaho, Stati Uniti, 83687
- Saint Luke's Cancer Institute - Nampa
-
Post Falls, Idaho, Stati Uniti, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint, Idaho, Stati Uniti, 83864
- Kootenai Clinic Cancer Services - Sandpoint
-
Twin Falls, Idaho, Stati Uniti, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Alton, Illinois, Stati Uniti, 62002
- OSF Saint Anthony's Health Center
-
Aurora, Illinois, Stati Uniti, 60504
- Rush-Copley Medical Center
-
Barrington, Illinois, Stati Uniti, 60010
- Advocate Good Shepherd Hospital
-
Bloomington, Illinois, Stati Uniti, 61704
- Illinois CancerCare-Bloomington
-
Canton, Illinois, Stati Uniti, 61520
- Illinois CancerCare-Canton
-
Carbondale, Illinois, Stati Uniti, 62902
- Memorial Hospital of Carbondale
-
Carterville, Illinois, Stati Uniti, 62918
- SIH Cancer Institute
-
Carthage, Illinois, Stati Uniti, 62321
- Illinois CancerCare-Carthage
-
Centralia, Illinois, Stati Uniti, 62801
- Centralia Oncology Clinic
-
Centralia, Illinois, Stati Uniti, 62801
- Saint Mary's Hospital
-
Chicago, Illinois, Stati Uniti, 60612
- University of Illinois
-
Chicago, Illinois, Stati Uniti, 60657
- Advocate Illinois Masonic Medical Center
-
Crystal Lake, Illinois, Stati Uniti, 60014
- AMG Crystal Lake - Oncology
-
Danville, Illinois, Stati Uniti, 61832
- Carle at The Riverfront
-
Decatur, Illinois, Stati Uniti, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Stati Uniti, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Dixon, Illinois, Stati Uniti, 61021
- Illinois CancerCare-Dixon
-
Downers Grove, Illinois, Stati Uniti, 60515
- Advocate Good Samaritan Hospital
-
Effingham, Illinois, Stati Uniti, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Stati Uniti, 62401
- Carle Physician Group-Effingham
-
Elgin, Illinois, Stati Uniti, 60123
- Advocate Sherman Hospital
-
Eureka, Illinois, Stati Uniti, 61530
- Illinois CancerCare-Eureka
-
Galesburg, Illinois, Stati Uniti, 61401
- Western Illinois Cancer Treatment Center
-
Galesburg, Illinois, Stati Uniti, 61401
- Illinois CancerCare-Galesburg
-
Hazel Crest, Illinois, Stati Uniti, 60429
- Advocate South Suburban Hospital
-
Hines, Illinois, Stati Uniti, 60141
- Edward Hines Jr VA Hospital
-
Kewanee, Illinois, Stati Uniti, 61443
- Illinois CancerCare-Kewanee Clinic
-
Libertyville, Illinois, Stati Uniti, 60048
- Condell Memorial Hospital
-
Libertyville, Illinois, Stati Uniti, 60048
- AMG Libertyville - Oncology
-
Macomb, Illinois, Stati Uniti, 61455
- Illinois CancerCare-Macomb
-
Mattoon, Illinois, Stati Uniti, 61938
- Carle Physician Group-Mattoon/Charleston
-
Mount Vernon, Illinois, Stati Uniti, 62864
- SSM Health Good Samaritan
-
O'Fallon, Illinois, Stati Uniti, 62269
- Cancer Care Center of O'Fallon
-
Oak Lawn, Illinois, Stati Uniti, 60453-2699
- Advocate Christ Medical Center
-
Ottawa, Illinois, Stati Uniti, 61350
- Illinois CancerCare-Ottawa Clinic
-
Park Ridge, Illinois, Stati Uniti, 60068
- Advocate Lutheran General Hospital
-
Pekin, Illinois, Stati Uniti, 61554
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Stati Uniti, 61636
- Methodist Medical Center of Illinois
-
Peoria, Illinois, Stati Uniti, 61615
- Illinois CancerCare-Peoria
-
Peru, Illinois, Stati Uniti, 61354
- Illinois CancerCare-Peru
-
Peru, Illinois, Stati Uniti, 61354
- Valley Radiation Oncology
-
Princeton, Illinois, Stati Uniti, 61356
- Illinois CancerCare-Princeton
-
Rockford, Illinois, Stati Uniti, 61114
- UW Health Carbone Cancer Center Rockford
-
Springfield, Illinois, Stati Uniti, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Stati Uniti, 62702
- Springfield Clinic
-
Springfield, Illinois, Stati Uniti, 62781
- Springfield Memorial Hospital
-
Swansea, Illinois, Stati Uniti, 62226
- Southwest Illinois Health Services LLP
-
Urbana, Illinois, Stati Uniti, 61801
- Carle Cancer Center
-
Urbana, Illinois, Stati Uniti, 61801
- The Carle Foundation Hospital
-
Washington, Illinois, Stati Uniti, 61571
- Illinois CancerCare - Washington
-
Yorkville, Illinois, Stati Uniti, 60560
- Rush-Copley Healthcare Center
-
-
Indiana
-
Richmond, Indiana, Stati Uniti, 47374
- Reid Health
-
South Bend, Indiana, Stati Uniti, 46601
- Memorial Hospital of South Bend
-
-
Iowa
-
Ames, Iowa, Stati Uniti, 50010
- Mary Greeley Medical Center
-
Ames, Iowa, Stati Uniti, 50010
- McFarland Clinic - Ames
-
Bettendorf, Iowa, Stati Uniti, 52722
- University of Iowa Healthcare Cancer Services Quad Cities
-
Boone, Iowa, Stati Uniti, 50036
- McFarland Clinic - Boone
-
Carroll, Iowa, Stati Uniti, 51401
- Saint Anthony Regional Hospital
-
Clive, Iowa, Stati Uniti, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Stati Uniti, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Council Bluffs, Iowa, Stati Uniti, 51503
- Alegent Health Mercy Hospital
-
Council Bluffs, Iowa, Stati Uniti, 51503
- Heartland Oncology and Hematology LLP
-
Council Bluffs, Iowa, Stati Uniti, 51503
- Methodist Jennie Edmundson Hospital
-
Creston, Iowa, Stati Uniti, 50801
- Greater Regional Medical Center
-
Des Moines, Iowa, Stati Uniti, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Stati Uniti, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Stati Uniti, 50314
- Broadlawns Medical Center
-
Des Moines, Iowa, Stati Uniti, 50316
- Iowa Lutheran Hospital
-
Des Moines, Iowa, Stati Uniti, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Stati Uniti, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Fort Dodge, Iowa, Stati Uniti, 50501
- McFarland Clinic - Trinity Cancer Center
-
Fort Dodge, Iowa, Stati Uniti, 50501
- UI Healthcare Mission Cancer and Blood - Fort Dodge
-
Iowa City, Iowa, Stati Uniti, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
Jefferson, Iowa, Stati Uniti, 50129
- McFarland Clinic - Jefferson
-
Marshalltown, Iowa, Stati Uniti, 50158
- McFarland Clinic - Marshalltown
-
West Des Moines, Iowa, Stati Uniti, 50266-7700
- Methodist West Hospital
-
West Des Moines, Iowa, Stati Uniti, 50266
- Mercy Medical Center-West Lakes
-
-
Kansas
-
Garden City, Kansas, Stati Uniti, 67846
- Central Care Cancer Center - Garden City
-
Great Bend, Kansas, Stati Uniti, 67530
- Central Care Cancer Center - Great Bend
-
Hays, Kansas, Stati Uniti, 67601
- HaysMed
-
Lawrence, Kansas, Stati Uniti, 66044
- Lawrence Memorial Hospital
-
Olathe, Kansas, Stati Uniti, 66061
- The University of Kansas Cancer Center - Olathe
-
Overland Park, Kansas, Stati Uniti, 66213
- Saint Luke's South Hospital
-
Pittsburg, Kansas, Stati Uniti, 66762
- Freeman Physician Group of Pittsburg
-
Pittsburg, Kansas, Stati Uniti, 66762
- Mercy Hospital Pittsburg
-
Salina, Kansas, Stati Uniti, 67401
- Salina Regional Health Center
-
Topeka, Kansas, Stati Uniti, 66606
- University of Kansas Health System Saint Francis Campus
-
-
Kentucky
-
Bardstown, Kentucky, Stati Uniti, 40004
- CommonSpirit Saint Joseph Hospital - Bardstown
-
Corbin, Kentucky, Stati Uniti, 40701
- Commonwealth Cancer Center-Corbin
-
Lexington, Kentucky, Stati Uniti, 40504
- Saint Joseph Radiation Oncology Resource Center
-
Lexington, Kentucky, Stati Uniti, 40509
- CommonSpirit Saint Joseph Medical Center - East Lexington
-
Lexington, Kentucky, Stati Uniti, 40504
- CommonSpirit Saint Joseph Hospital - Lexington
-
London, Kentucky, Stati Uniti, 40741
- CommonSpirit Saint Joseph Hospital London
-
Louisville, Kentucky, Stati Uniti, 40202
- Jewish Hospital
-
Louisville, Kentucky, Stati Uniti, 40245
- UofL Health Medical Center Northeast
-
Louisville, Kentucky, Stati Uniti, 40215
- Saints Mary and Elizabeth Hospital
-
Mount Sterling, Kentucky, Stati Uniti, 40353
- CommonSpirit Saint Joseph Hospital Mount Sterling
-
Owensboro, Kentucky, Stati Uniti, 42303
- Owensboro Health Mitchell Memorial Cancer Center
-
Paducah, Kentucky, Stati Uniti, 42003
- Mercy Health - Paducah Cancer Center
-
Shepherdsville, Kentucky, Stati Uniti, 40165
- Jewish Hospital Medical Center South
-
-
Louisiana
-
Baton Rouge, Louisiana, Stati Uniti, 70805
- LSU Health Baton Rouge-North Clinic
-
Baton Rouge, Louisiana, Stati Uniti, 70809
- Louisiana Hematology Oncology Associates LLC
-
Baton Rouge, Louisiana, Stati Uniti, 70809
- Mary Bird Perkins Cancer Center
-
Baton Rouge, Louisiana, Stati Uniti, 70808
- Our Lady of The Lake
-
Baton Rouge, Louisiana, Stati Uniti, 70808
- Our Lady of the Lake Physician Group
-
Covington, Louisiana, Stati Uniti, 70433
- Northshore Oncology Associates-Covington
-
Houma, Louisiana, Stati Uniti, 70360
- Terrebonne General Medical Center
-
-
Maine
-
Augusta, Maine, Stati Uniti, 04330
- Harold Alfond Center for Cancer Care
-
Biddeford, Maine, Stati Uniti, 04005
- MaineHealth Maine Medical Center - Biddeford
-
Sanford, Maine, Stati Uniti, 04073
- MaineHealth Cancer Care and IV Therapy - Sanford
-
South Portland, Maine, Stati Uniti, 04106
- MaineHealth Cancer Care and IV Therapy - South Portland
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21229
- Saint Agnes Hospital
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02118
- Boston Medical Center
-
Worcester, Massachusetts, Stati Uniti, 01655
- UMass Memorial Medical Center - University Campus
-
-
Michigan
-
Adrian, Michigan, Stati Uniti, 49221
- Hickman Cancer Center
-
Ann Arbor, Michigan, Stati Uniti, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Battle Creek, Michigan, Stati Uniti, 49017
- Bronson Battle Creek
-
Brighton, Michigan, Stati Uniti, 48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton, Michigan, Stati Uniti, 48114
- Trinity Health Medical Center - Brighton
-
Canton, Michigan, Stati Uniti, 48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton, Michigan, Stati Uniti, 48188
- Trinity Health Medical Center - Canton
-
Caro, Michigan, Stati Uniti, 48723
- Caro Cancer Center
-
Chelsea, Michigan, Stati Uniti, 48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea, Michigan, Stati Uniti, 48118
- Chelsea Hospital
-
Clarkston, Michigan, Stati Uniti, 48346
- Hematology Oncology Consultants-Clarkston
-
Clarkston, Michigan, Stati Uniti, 48346
- Newland Medical Associates-Clarkston
-
Detroit, Michigan, Stati Uniti, 48236
- Henry Ford Health Saint John Hospital
-
East China Township, Michigan, Stati Uniti, 48054
- Henry Ford River District Hospital
-
Flint, Michigan, Stati Uniti, 48503
- Hurley Medical Center
-
Flint, Michigan, Stati Uniti, 48503
- Genesee Hematology Oncology PC
-
Flint, Michigan, Stati Uniti, 48503
- Genesys Hurley Cancer Institute
-
Flint, Michigan, Stati Uniti, 48503
- Cancer Hematology Centers - Flint
-
Grand Rapids, Michigan, Stati Uniti, 49503
- Trinity Health Grand Rapids Hospital
-
Grand Rapids, Michigan, Stati Uniti, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Grand Rapids, Michigan, Stati Uniti, 49503
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Grosse Pointe Woods, Michigan, Stati Uniti, 48236
- Henry Ford Saint John Hospital - Academic
-
Grosse Pointe Woods, Michigan, Stati Uniti, 48236
- Henry Ford Saint John Hospital - Breast
-
Grosse Pointe Woods, Michigan, Stati Uniti, 48236
- Henry Ford Saint John Hospital - Van Elslander
-
Kalamazoo, Michigan, Stati Uniti, 49007
- West Michigan Cancer Center
-
Kalamazoo, Michigan, Stati Uniti, 49007
- Bronson Methodist Hospital
-
Kalamazoo, Michigan, Stati Uniti, 49009
- Beacon Kalamazoo Cancer Center
-
Kalamazoo, Michigan, Stati Uniti, 49048
- Beacon Kalamazoo
-
Lansing, Michigan, Stati Uniti, 48912
- University of Michigan Health - Sparrow Lansing
-
Livonia, Michigan, Stati Uniti, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Livonia, Michigan, Stati Uniti, 48154
- Hope Cancer Clinic
-
Macomb, Michigan, Stati Uniti, 48044
- Henry Ford Warren Hospital - Breast Macomb
-
Macomb, Michigan, Stati Uniti, 48044
- Henry Ford Saint John Hospital - Macomb Medical
-
Marlette, Michigan, Stati Uniti, 48453
- Saint Mary's Oncology/Hematology Associates of Marlette
-
Monroe, Michigan, Stati Uniti, 48162
- Toledo Clinic Cancer Centers-Monroe
-
Muskegon, Michigan, Stati Uniti, 49444
- Trinity Health Muskegon Hospital
-
Niles, Michigan, Stati Uniti, 49120
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Norton Shores, Michigan, Stati Uniti, 49444
- Cancer and Hematology Centers of Western Michigan - Norton Shores
-
Novi, Michigan, Stati Uniti, 48374
- Henry Ford Health Providence Novi Hospital
-
Pontiac, Michigan, Stati Uniti, 48341
- Hope Cancer Center
-
Pontiac, Michigan, Stati Uniti, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Pontiac, Michigan, Stati Uniti, 48341
- Michigan Healthcare Professionals Pontiac
-
Pontiac, Michigan, Stati Uniti, 48341
- Trinity Health IHA Medical Group-Alice Gustafson Center
-
Reed City, Michigan, Stati Uniti, 49677
- Corewell Health Reed City Hospital
-
Rochester Hills, Michigan, Stati Uniti, 48309
- Henry Ford Rochester Hospital
-
Saginaw, Michigan, Stati Uniti, 48604
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, Stati Uniti, 48601
- MyMichigan Medical Center Saginaw
-
Saint Joseph, Michigan, Stati Uniti, 49085
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Saint Joseph, Michigan, Stati Uniti, 49085
- Corewell Health Lakeland Hospitals - Saint Joseph Hospital
-
Southfield, Michigan, Stati Uniti, 48075
- Henry Ford Health Providence Southfield Hospital
-
Sterling Heights, Michigan, Stati Uniti, 48312
- Bhadresh Nayak MD PC-Sterling Heights
-
Tawas City, Michigan, Stati Uniti, 48764
- MyMichigan Medical Center Tawas
-
Traverse City, Michigan, Stati Uniti, 49684
- Munson Medical Center
-
Warren, Michigan, Stati Uniti, 48088
- Advanced Breast Care Center PLLC
-
Warren, Michigan, Stati Uniti, 48093
- Macomb Hematology Oncology PC
-
Warren, Michigan, Stati Uniti, 48093
- Henry Ford Madison Heights Hospital - Breast
-
Warren, Michigan, Stati Uniti, 48093
- Henry Ford Health Warren Hospital
-
Warren, Michigan, Stati Uniti, 48093
- Henry Ford Warren Hospital - GLCMS
-
West Branch, Michigan, Stati Uniti, 48661
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Wyoming, Michigan, Stati Uniti, 49519
- University of Michigan Health - West
-
Ypsilanti, Michigan, Stati Uniti, 48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
Ypsilanti, Michigan, Stati Uniti, 48106
- Huron Gastroenterology PC
-
-
Minnesota
-
Aitkin, Minnesota, Stati Uniti, 56431
- Riverwood Healthcare Center
-
Baxter, Minnesota, Stati Uniti, 56425
- Essentia Health - Baxter Clinic
-
Brainerd, Minnesota, Stati Uniti, 56401
- Essentia Health Saint Joseph's Medical Center
-
Burnsville, Minnesota, Stati Uniti, 55337
- Fairview Ridges Hospital
-
Burnsville, Minnesota, Stati Uniti, 55337
- Minnesota Oncology - Burnsville
-
Cambridge, Minnesota, Stati Uniti, 55008
- Cambridge Medical Center
-
Coon Rapids, Minnesota, Stati Uniti, 55433
- Mercy Hospital
-
Deer River, Minnesota, Stati Uniti, 56636
- Essentia Health - Deer River Clinic
-
Detroit Lakes, Minnesota, Stati Uniti, 56501
- Essentia Health Saint Mary's - Detroit Lakes Clinic
-
Duluth, Minnesota, Stati Uniti, 55805
- Essentia Health Cancer Center
-
Duluth, Minnesota, Stati Uniti, 55805
- Essentia Health Saint Mary's Medical Center
-
Duluth, Minnesota, Stati Uniti, 55805
- Miller-Dwan Hospital
-
Edina, Minnesota, Stati Uniti, 55435
- Fairview Southdale Hospital
-
Ely, Minnesota, Stati Uniti, 55731
- Essentia Health - Ely Clinic
-
Fergus Falls, Minnesota, Stati Uniti, 56537
- Lake Region Healthcare Corporation-Cancer Care
-
Fosston, Minnesota, Stati Uniti, 56542
- Essentia Health - Fosston
-
Fridley, Minnesota, Stati Uniti, 55432
- Unity Hospital
-
Hibbing, Minnesota, Stati Uniti, 55746
- Essentia Health Hibbing Clinic
-
International Falls, Minnesota, Stati Uniti, 56649
- Essentia Health - International Falls Clinic
-
Maple Grove, Minnesota, Stati Uniti, 55369
- Fairview Clinics and Surgery Center Maple Grove
-
Maplewood, Minnesota, Stati Uniti, 55109
- Saint John's Hospital - Healtheast
-
Maplewood, Minnesota, Stati Uniti, 55109
- Minnesota Oncology Hematology PA-Maplewood
-
Minneapolis, Minnesota, Stati Uniti, 55415
- Hennepin County Medical Center
-
Minneapolis, Minnesota, Stati Uniti, 55407
- Abbott-Northwestern Hospital
-
Minneapolis, Minnesota, Stati Uniti, 55454
- Health Partners Inc
-
Monticello, Minnesota, Stati Uniti, 55362
- Monticello Cancer Center
-
Moose Lake, Minnesota, Stati Uniti, 55767
- Essentia Health - Moose Lake Clinic
-
New Ulm, Minnesota, Stati Uniti, 56073
- New Ulm Medical Center
-
Park Rapids, Minnesota, Stati Uniti, 56470
- Essentia Health - Park Rapids
-
Princeton, Minnesota, Stati Uniti, 55371
- Fairview Northland Medical Center
-
Robbinsdale, Minnesota, Stati Uniti, 55422
- North Memorial Medical Health Center
-
Saint Louis Park, Minnesota, Stati Uniti, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul, Minnesota, Stati Uniti, 55101
- Regions Hospital
-
Saint Paul, Minnesota, Stati Uniti, 55102
- United Hospital
-
Sandstone, Minnesota, Stati Uniti, 55072
- Essentia Health Sandstone
-
Shakopee, Minnesota, Stati Uniti, 55379
- Saint Francis Regional Medical Center
-
Stillwater, Minnesota, Stati Uniti, 55082
- Lakeview Hospital
-
Virginia, Minnesota, Stati Uniti, 55792
- Essentia Health Virginia Clinic
-
Waconia, Minnesota, Stati Uniti, 55387
- Ridgeview Medical Center
-
Willmar, Minnesota, Stati Uniti, 56201
- Rice Memorial Hospital
-
Woodbury, Minnesota, Stati Uniti, 55125
- Minnesota Oncology Hematology PA-Woodbury
-
Wyoming, Minnesota, Stati Uniti, 55092
- Fairview Lakes Medical Center
-
-
Missouri
-
Ballwin, Missouri, Stati Uniti, 63011
- Mercy Oncology and Hematology - Clayton-Clarkson
-
Bolivar, Missouri, Stati Uniti, 65613
- Central Care Cancer Center - Bolivar
-
Branson, Missouri, Stati Uniti, 65616
- Cox Cancer Center Branson
-
Cape Girardeau, Missouri, Stati Uniti, 63703
- Saint Francis Medical Center
-
Cape Girardeau, Missouri, Stati Uniti, 63703
- Mercy Cancer Center - Cape Girardeau
-
City of Saint Peters, Missouri, Stati Uniti, 63376
- Siteman Cancer Center at Saint Peters Hospital
-
Columbia, Missouri, Stati Uniti, 65212
- MU Health - University Hospital/Ellis Fischel Cancer Center
-
Creve Coeur, Missouri, Stati Uniti, 63141
- Siteman Cancer Center at West County Hospital
-
Farmington, Missouri, Stati Uniti, 63640
- Parkland Health Center - Farmington
-
Jefferson City, Missouri, Stati Uniti, 65109
- MU Health Care Goldschmidt Cancer Center
-
Joplin, Missouri, Stati Uniti, 64804
- Freeman Health System
-
Joplin, Missouri, Stati Uniti, 64804
- Mercy Hospital Joplin
-
Kansas City, Missouri, Stati Uniti, 64111
- Saint Luke's Hospital of Kansas City
-
Kansas City, Missouri, Stati Uniti, 64108
- University Health Truman Medical Center
-
Lee's Summit, Missouri, Stati Uniti, 64086
- Saint Luke's East - Lee's Summit
-
Rolla, Missouri, Stati Uniti, 65401
- Mercy Clinic-Rolla-Cancer and Hematology
-
Rolla, Missouri, Stati Uniti, 65401
- Phelps Health Delbert Day Cancer Institute
-
Saint Joseph, Missouri, Stati Uniti, 64506
- Heartland Regional Medical Center
-
Sainte Genevieve, Missouri, Stati Uniti, 63670
- Sainte Genevieve County Memorial Hospital
-
Springfield, Missouri, Stati Uniti, 65807
- CoxHealth South Hospital
-
Springfield, Missouri, Stati Uniti, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, Stati Uniti, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Stati Uniti, 63129
- Siteman Cancer Center-South County
-
St Louis, Missouri, Stati Uniti, 63136
- Siteman Cancer Center at Christian Hospital
-
St Louis, Missouri, Stati Uniti, 63131
- Missouri Baptist Medical Center
-
St Louis, Missouri, Stati Uniti, 63109
- Mercy Infusion Center - Chippewa
-
St Louis, Missouri, Stati Uniti, 63141
- Mercy Hospital Saint Louis
-
St Louis, Missouri, Stati Uniti, 63128
- Mercy Hospital South
-
Sullivan, Missouri, Stati Uniti, 63080
- Missouri Baptist Sullivan Hospital
-
Washington, Missouri, Stati Uniti, 63090
- Mercy Hospital Washington
-
-
Montana
-
Anaconda, Montana, Stati Uniti, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Stati Uniti, 59101
- Billings Clinic Cancer Center
-
Billings, Montana, Stati Uniti, 59101
- Saint Vincent Healthcare
-
Billings, Montana, Stati Uniti, 59102
- Saint Vincent Frontier Cancer Center
-
Bozeman, Montana, Stati Uniti, 59715
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, Stati Uniti, 59405
- Great Falls Clinic
-
Great Falls, Montana, Stati Uniti, 59405
- Benefis Sletten Cancer Institute
-
Kalispell, Montana, Stati Uniti, 59901
- Logan Health Medical Center
-
Missoula, Montana, Stati Uniti, 59802
- Saint Patrick Hospital - Community Hospital
-
Missoula, Montana, Stati Uniti, 59804
- Community Medical Center
-
-
Nebraska
-
Bellevue, Nebraska, Stati Uniti, 68123
- Nebraska Medicine-Bellevue
-
Grand Island, Nebraska, Stati Uniti, 68803
- Nebraska Cancer Specialists/Oncology Hematology West PC
-
Kearney, Nebraska, Stati Uniti, 68847
- CHI Health Good Samaritan
-
Lincoln, Nebraska, Stati Uniti, 68510
- Saint Elizabeth Regional Medical Center
-
Omaha, Nebraska, Stati Uniti, 68114
- Nebraska Methodist Hospital
-
Omaha, Nebraska, Stati Uniti, 68198
- University of Nebraska Medical Center
-
Omaha, Nebraska, Stati Uniti, 68124
- Alegent Health Bergan Mercy Medical Center
-
Omaha, Nebraska, Stati Uniti, 68118
- Nebraska Medicine-Village Pointe
-
Omaha, Nebraska, Stati Uniti, 68122
- Alegent Health Immanuel Medical Center
-
Omaha, Nebraska, Stati Uniti, 68130
- Alegent Health Lakeside Hospital
-
Omaha, Nebraska, Stati Uniti, 68114
- Oncology Associates PC
-
Omaha, Nebraska, Stati Uniti, 68114
- Nebraska Cancer Specialists/Oncology Hematology West PC - MECC
-
Papillion, Nebraska, Stati Uniti, 68046
- Midlands Community Hospital
-
-
Nevada
-
Carson City, Nevada, Stati Uniti, 89703
- Carson Tahoe Regional Medical Center
-
Henderson, Nevada, Stati Uniti, 89052
- Comprehensive Cancer Centers of Nevada - Henderson
-
Henderson, Nevada, Stati Uniti, 89052
- Cancer and Blood Specialists-Henderson
-
Henderson, Nevada, Stati Uniti, 89052
- Las Vegas Cancer Center-Henderson
-
Henderson, Nevada, Stati Uniti, 89074
- Comprehensive Cancer Centers of Nevada-Southeast Henderson
-
Henderson, Nevada, Stati Uniti, 89052
- Comprehensive Cancer Centers of Nevada-Horizon Ridge
-
Henderson, Nevada, Stati Uniti, 89074
- Las Vegas Urology - Green Valley
-
Henderson, Nevada, Stati Uniti, 89074
- Las Vegas Urology - Pebble
-
Henderson, Nevada, Stati Uniti, 89074
- Urology Specialists of Nevada - Green Valley
-
Henderson, Nevada, Stati Uniti, 89074
- Oncology Las Vegas - Henderson
-
Las Vegas, Nevada, Stati Uniti, 89144
- Summerlin Hospital Medical Center
-
Las Vegas, Nevada, Stati Uniti, 89109
- Sunrise Hospital and Medical Center
-
Las Vegas, Nevada, Stati Uniti, 89102
- OptumCare Cancer Care at Charleston
-
Las Vegas, Nevada, Stati Uniti, 89106
- Radiation Oncology Centers of Nevada Central
-
Las Vegas, Nevada, Stati Uniti, 89119
- Radiation Oncology Centers of Nevada Southeast
-
Las Vegas, Nevada, Stati Uniti, 89128
- Comprehensive Cancer Centers of Nevada - Northwest
-
Las Vegas, Nevada, Stati Uniti, 89128
- OptumCare Cancer Care at MountainView
-
Las Vegas, Nevada, Stati Uniti, 89135
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Las Vegas, Nevada, Stati Uniti, 89144
- Comprehensive Cancer Centers of Nevada - Town Center
-
Las Vegas, Nevada, Stati Uniti, 89144
- Comprehensive Cancer Centers of Nevada-Summerlin
-
Las Vegas, Nevada, Stati Uniti, 89148
- Comprehensive Cancer Centers of Nevada
-
Las Vegas, Nevada, Stati Uniti, 89169
- Comprehensive Cancer Centers of Nevada - Central Valley
-
Las Vegas, Nevada, Stati Uniti, 89102
- University Medical Center of Southern Nevada
-
Las Vegas, Nevada, Stati Uniti, 89106
- Cancer and Blood Specialists-Shadow
-
Las Vegas, Nevada, Stati Uniti, 89109
- HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway
-
Las Vegas, Nevada, Stati Uniti, 89113
- HealthCare Partners Medical Group Oncology/Hematology-San Martin
-
Las Vegas, Nevada, Stati Uniti, 89128
- Cancer and Blood Specialists-Tenaya
-
Las Vegas, Nevada, Stati Uniti, 89128
- HealthCare Partners Medical Group Oncology/Hematology-Tenaya
-
Las Vegas, Nevada, Stati Uniti, 89148-2405
- Las Vegas Cancer Center-Medical Center
-
Las Vegas, Nevada, Stati Uniti, 89149
- HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills
-
Las Vegas, Nevada, Stati Uniti, 89128
- Ann M Wierman MD LTD
-
Las Vegas, Nevada, Stati Uniti, 89074
- Las Vegas Urology - Pecos
-
Las Vegas, Nevada, Stati Uniti, 89102
- Desert West Surgery
-
Las Vegas, Nevada, Stati Uniti, 89103
- Hope Cancer Care of Nevada
-
Las Vegas, Nevada, Stati Uniti, 89106
- Urology Specialists of Nevada - Central
-
Las Vegas, Nevada, Stati Uniti, 89113
- Las Vegas Prostate Cancer Center
-
Las Vegas, Nevada, Stati Uniti, 89113
- Las Vegas Urology - Sunset
-
Las Vegas, Nevada, Stati Uniti, 89128
- Las Vegas Urology - Cathedral Rock
-
Las Vegas, Nevada, Stati Uniti, 89128
- Las Vegas Urology - Smoke Ranch
-
Las Vegas, Nevada, Stati Uniti, 89128
- Urology Specialists of Nevada - Northwest
-
Las Vegas, Nevada, Stati Uniti, 89169
- University Cancer Center
-
Las Vegas, Nevada, Stati Uniti, 89113
- Urology Specialists of Nevada - Southwest
-
Las Vegas, Nevada, Stati Uniti, 89128
- Oncology Las Vegas - Tenaya
-
Las Vegas, Nevada, Stati Uniti, 89183
- OptumCare Cancer Care at Fort Apache
-
Pahrump, Nevada, Stati Uniti, 89048
- Hope Cancer Care of Nevada-Pahrump
-
Reno, Nevada, Stati Uniti, 89502
- Renown Regional Medical Center
-
Reno, Nevada, Stati Uniti, 89503
- Saint Mary's Regional Medical Center
-
Reno, Nevada, Stati Uniti, 89509
- Radiation Oncology Associates
-
-
New Hampshire
-
Concord, New Hampshire, Stati Uniti, 03301
- New Hampshire Oncology Hematology PA-Concord
-
Manchester, New Hampshire, Stati Uniti, 03103
- Solinsky Center for Cancer Care
-
Manchester, New Hampshire, Stati Uniti, 03103
- Elliot Hospital
-
-
New Jersey
-
Moorestown, New Jersey, Stati Uniti, 08057
- Virtua Samson Cancer Center
-
Mount Holly, New Jersey, Stati Uniti, 08060
- Virtua Memorial
-
Voorhees Township, New Jersey, Stati Uniti, 08043
- Virtua Voorhees
-
-
New Mexico
-
Albuquerque, New Mexico, Stati Uniti, 87106
- University of New Mexico Cancer Center
-
-
New York
-
Glens Falls, New York, Stati Uniti, 12801
- Glens Falls Hospital
-
The Bronx, New York, Stati Uniti, 10461
- Montefiore Medical Center-Einstein Campus
-
The Bronx, New York, Stati Uniti, 10467
- Montefiore Medical Center - Moses Campus
-
The Bronx, New York, Stati Uniti, 10461
- Montefiore Medical Center-Weiler Hospital
-
-
North Carolina
-
Kenansville, North Carolina, Stati Uniti, 28349
- ECU Health Oncology Kenansville
-
Kinston, North Carolina, Stati Uniti, 28501
- ECU Health Oncology Kinston
-
Pinehurst, North Carolina, Stati Uniti, 28374
- FirstHealth of the Carolinas-Moore Regional Hospital
-
Richlands, North Carolina, Stati Uniti, 28574
- ECU Health Oncology Richlands
-
Washington, North Carolina, Stati Uniti, 27889
- Marion L Shepard Cancer Center - ECU Health Beaufort Hospital
-
-
North Dakota
-
Fargo, North Dakota, Stati Uniti, 58103
- Essentia Health Cancer Center-South University Clinic
-
Jamestown, North Dakota, Stati Uniti, 58401
- Essentia Health - Jamestown Clinic
-
-
Ohio
-
Alliance, Ohio, Stati Uniti, 44601
- Aultman Alliance Community Hospital
-
Beavercreek, Ohio, Stati Uniti, 45431
- Indu and Raj Soin Medical Center
-
Boardman, Ohio, Stati Uniti, 44512
- Saint Elizabeth Boardman Hospital
-
Canton, Ohio, Stati Uniti, 44708
- Cleveland Clinic Mercy Hospital
-
Canton, Ohio, Stati Uniti, 44710
- Aultman Health Foundation
-
Centerville, Ohio, Stati Uniti, 45459
- Miami Valley Hospital South
-
Centerville, Ohio, Stati Uniti, 45459
- Dayton Physicians LLC-Miami Valley South
-
Cincinnati, Ohio, Stati Uniti, 45220
- Good Samaritan Hospital - Cincinnati
-
Cincinnati, Ohio, Stati Uniti, 45242
- Bethesda North Hospital
-
Cincinnati, Ohio, Stati Uniti, 45236
- Oncology Hematology Care Inc-Kenwood
-
Cincinnati, Ohio, Stati Uniti, 45247
- TriHealth Cancer Institute-Westside
-
Cincinnati, Ohio, Stati Uniti, 45255
- TriHealth Cancer Institute-Anderson
-
Cleveland, Ohio, Stati Uniti, 44195
- Cleveland Clinic Foundation
-
Cleveland, Ohio, Stati Uniti, 44111
- Cleveland Clinic Cancer Center/Fairview Hospital
-
Dayton, Ohio, Stati Uniti, 45409
- Miami Valley Hospital
-
Dayton, Ohio, Stati Uniti, 45415
- Miami Valley Hospital North
-
Dayton, Ohio, Stati Uniti, 45415
- Dayton Physician LLC - Englewood
-
Dayton, Ohio, Stati Uniti, 45409
- Premier Blood and Cancer Center
-
Findlay, Ohio, Stati Uniti, 45840
- Blanchard Valley Hospital
-
Findlay, Ohio, Stati Uniti, 45840
- Armes Family Cancer Center
-
Findlay, Ohio, Stati Uniti, 45840
- Orion Cancer Care
-
Franklin, Ohio, Stati Uniti, 45005-1066
- Atrium Medical Center-Middletown Regional Hospital
-
Franklin, Ohio, Stati Uniti, 45005
- Dayton Physicians LLC-Atrium
-
Greenville, Ohio, Stati Uniti, 45331
- Wayne Hospital
-
Greenville, Ohio, Stati Uniti, 45331
- Dayton Physicians LLC-Wayne
-
Greenville, Ohio, Stati Uniti, 45331
- Miami Valley Cancer Care and Infusion
-
Kettering, Ohio, Stati Uniti, 45429
- Kettering Medical Center
-
Kettering, Ohio, Stati Uniti, 45409
- Greater Dayton Cancer Center
-
Kettering, Ohio, Stati Uniti, 45420
- First Dayton Cancer Care
-
Mansfield, Ohio, Stati Uniti, 44906
- Cleveland Clinic Cancer Center Mansfield
-
Maumee, Ohio, Stati Uniti, 43537
- Toledo Clinic Cancer Centers-Maumee
-
Mayfield Heights, Ohio, Stati Uniti, 44124
- Hillcrest Hospital Cancer Center
-
Perrysburg, Ohio, Stati Uniti, 43551
- Mercy Health - Perrysburg Hospital
-
Sandusky, Ohio, Stati Uniti, 44870
- North Coast Cancer Care
-
Springfield, Ohio, Stati Uniti, 45504
- Springfield Regional Cancer Center
-
Springfield, Ohio, Stati Uniti, 45504
- Springfield Regional Medical Center
-
Strongsville, Ohio, Stati Uniti, 44136
- Cleveland Clinic Cancer Center Strongsville
-
Toledo, Ohio, Stati Uniti, 43623
- Mercy Health - Saint Anne Hospital
-
Toledo, Ohio, Stati Uniti, 43623
- Toledo Clinic Cancer Centers-Toledo
-
Troy, Ohio, Stati Uniti, 45373
- Upper Valley Medical Center
-
Troy, Ohio, Stati Uniti, 45373
- Dayton Physicians LLC - Troy
-
Warren, Ohio, Stati Uniti, 44484
- Saint Joseph Warren Hospital
-
Warrensville Heights, Ohio, Stati Uniti, 44122
- South Pointe Hospital
-
Wooster, Ohio, Stati Uniti, 44691
- Cleveland Clinic Wooster Family Health and Surgery Center
-
Wright-Patterson Air Force Base, Ohio, Stati Uniti, 45433
- Wright-Patterson Medical Center
-
Youngstown, Ohio, Stati Uniti, 44501
- Saint Elizabeth Youngstown Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stati Uniti, 73120
- Mercy Hospital Oklahoma City
-
-
Oregon
-
Baker City, Oregon, Stati Uniti, 97814
- Saint Alphonsus Cancer Care Center-Baker City
-
Bend, Oregon, Stati Uniti, 97701
- Saint Charles Health System
-
Clackamas, Oregon, Stati Uniti, 97015
- Clackamas Radiation Oncology Center
-
Clackamas, Oregon, Stati Uniti, 97015
- Providence Cancer Institute Clackamas Clinic
-
Coos Bay, Oregon, Stati Uniti, 97420
- Bay Area Hospital
-
Newberg, Oregon, Stati Uniti, 97132
- Providence Newberg Medical Center
-
Ontario, Oregon, Stati Uniti, 97914
- Saint Alphonsus Cancer Care Center-Ontario
-
Oregon City, Oregon, Stati Uniti, 97045
- Providence Willamette Falls Medical Center
-
Portland, Oregon, Stati Uniti, 97239
- Oregon Health and Science University
-
Portland, Oregon, Stati Uniti, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Stati Uniti, 97225
- Providence Saint Vincent Medical Center
-
Redmond, Oregon, Stati Uniti, 97756
- Saint Charles Health System-Redmond
-
-
Pennsylvania
-
Allentown, Pennsylvania, Stati Uniti, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Allentown, Pennsylvania, Stati Uniti, 18104
- Saint Luke's Cancer Center - Allentown
-
Bethlehem, Pennsylvania, Stati Uniti, 18017
- Lehigh Valley Hospital - Muhlenberg
-
Bethlehem, Pennsylvania, Stati Uniti, 18015
- Saint Luke's University Hospital-Bethlehem Campus
-
Bryn Mawr, Pennsylvania, Stati Uniti, 19010
- Bryn Mawr Hospital
-
Chambersburg, Pennsylvania, Stati Uniti, 17201
- Chambersburg Hospital
-
Chambersburg, Pennsylvania, Stati Uniti, 17201
- WellSpan Medical Oncology and Hematology
-
Collegeville, Pennsylvania, Stati Uniti, 19426
- Main Line Health Center-Collegeville
-
East Stroudsburg, Pennsylvania, Stati Uniti, 18301
- Pocono Medical Center
-
Easton, Pennsylvania, Stati Uniti, 18045
- Saint Luke's Hospital-Anderson Campus
-
Ephrata, Pennsylvania, Stati Uniti, 17522
- Ephrata Cancer Center
-
Exton, Pennsylvania, Stati Uniti, 19341
- Main Line Health Center-Exton
-
Gettysburg, Pennsylvania, Stati Uniti, 17325
- Adams Cancer Center
-
Hanover, Pennsylvania, Stati Uniti, 17331
- WellSpan Medical Oncology and Hematology
-
Hazleton, Pennsylvania, Stati Uniti, 18201
- Lehigh Valley Hospital-Hazleton
-
Lebanon, Pennsylvania, Stati Uniti, 17042
- Sechler Family Cancer Center
-
Media, Pennsylvania, Stati Uniti, 19063
- Riddle Memorial Hospital
-
Newtown Square, Pennsylvania, Stati Uniti, 19073
- Bryn Mawr Health Center
-
Paoli, Pennsylvania, Stati Uniti, 19301
- Paoli Memorial Hospital
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- University of Pennsylvania/Abramson Cancer Center
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- Penn Presbyterian Medical Center
-
Pottstown, Pennsylvania, Stati Uniti, 19464
- Pottstown Hospital
-
Quakertown, Pennsylvania, Stati Uniti, 18951
- Saint Luke's Hospital-Quakertown Campus
-
Quakertown, Pennsylvania, Stati Uniti, 18951
- Saint Luke's Hospital - Upper Bucks Campus
-
Sayre, Pennsylvania, Stati Uniti, 18840
- Guthrie Medical Group PC-Robert Packer Hospital
-
Wynnewood, Pennsylvania, Stati Uniti, 19096
- Lankenau Medical Center
-
York, Pennsylvania, Stati Uniti, 17403
- WellSpan Health-York Cancer Center
-
York, Pennsylvania, Stati Uniti, 17403
- WellSpan Health-York Hospital
-
York, Pennsylvania, Stati Uniti, 17403
- Cancer Care Associates of York
-
-
South Carolina
-
Greenwood, South Carolina, Stati Uniti, 29646
- Self Regional Healthcare
-
-
Texas
-
Bryan, Texas, Stati Uniti, 77802
- Saint Joseph Regional Cancer Center
-
-
Virginia
-
Mechanicsville, Virginia, Stati Uniti, 23116
- Bon Secours Memorial Regional Medical Center
-
Midlothian, Virginia, Stati Uniti, 23114
- Bon Secours Saint Francis Medical Center
-
Midlothian, Virginia, Stati Uniti, 23113
- Bon Secours Westchester Emergency Center
-
Norfolk, Virginia, Stati Uniti, 23505
- Bon Secours DePaul Medical Center
-
Portsmouth, Virginia, Stati Uniti, 23707
- Bon Secours Maryview Medical Center
-
Richmond, Virginia, Stati Uniti, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, Stati Uniti, 23226
- Bon Secours Saint Mary's Hospital
-
Richmond, Virginia, Stati Uniti, 23230
- Bon Secours Cancer Institute at Reynolds Crossing
-
Richmond, Virginia, Stati Uniti, 23223
- Bon Secours Richmond Community Hospital
-
Richmond, Virginia, Stati Uniti, 23298
- VCU Massey Comprehensive Cancer Center
-
Suffolk, Virginia, Stati Uniti, 23435
- Bon Secours Health Center at Harbour View
-
-
Washington
-
Aberdeen, Washington, Stati Uniti, 98520
- Providence Regional Cancer System-Aberdeen
-
Bellevue, Washington, Stati Uniti, 98004
- Overlake Medical Center
-
Bellingham, Washington, Stati Uniti, 98225
- PeaceHealth Saint Joseph Medical Center
-
Burien, Washington, Stati Uniti, 98166
- Saint Anne Hospital
-
Centralia, Washington, Stati Uniti, 98531
- Providence Regional Cancer System-Centralia
-
Edmonds, Washington, Stati Uniti, 98026
- Swedish Cancer Institute-Edmonds
-
Enumclaw, Washington, Stati Uniti, 98022
- Saint Elizabeth Hospital
-
Everett, Washington, Stati Uniti, 98201
- Providence Regional Cancer Partnership
-
Federal Way, Washington, Stati Uniti, 98003
- Saint Francis Hospital
-
Issaquah, Washington, Stati Uniti, 98029
- Swedish Cancer Institute-Issaquah
-
Kennewick, Washington, Stati Uniti, 99336
- Kadlec Clinic Hematology and Oncology
-
Lacey, Washington, Stati Uniti, 98503
- Providence Regional Cancer System-Lacey
-
Lakewood, Washington, Stati Uniti, 98499
- Saint Clare Hospital
-
Longview, Washington, Stati Uniti, 98632
- PeaceHealth Saint John Medical Center
-
Port Townsend, Washington, Stati Uniti, 98368
- Jefferson Healthcare
-
Poulsbo, Washington, Stati Uniti, 98370
- Harrison HealthPartners Hematology and Oncology-Poulsbo
-
Renton, Washington, Stati Uniti, 98055
- Valley Medical Center
-
Seattle, Washington, Stati Uniti, 98107
- Swedish Medical Center-Ballard Campus
-
Seattle, Washington, Stati Uniti, 98122
- Swedish Medical Center-First Hill
-
Seattle, Washington, Stati Uniti, 98104
- Pacific Gynecology Specialists
-
Seattle, Washington, Stati Uniti, 98122-5711
- Swedish Medical Center-Cherry Hill
-
Sedro-Woolley, Washington, Stati Uniti, 98284
- PeaceHealth United General Medical Center
-
Shelton, Washington, Stati Uniti, 98584
- Providence Regional Cancer System-Shelton
-
Silverdale, Washington, Stati Uniti, 98383
- Saint Joseph Medical Center Hematology and Oncology - Silverdale
-
Tacoma, Washington, Stati Uniti, 98405
- Northwest Medical Specialties PLLC
-
Tacoma, Washington, Stati Uniti, 98405
- Franciscan Research Center-Northwest Medical Plaza
-
Vancouver, Washington, Stati Uniti, 98664
- PeaceHealth Southwest Medical Center
-
Walla Walla, Washington, Stati Uniti, 99362
- Providence Saint Mary Regional Cancer Center
-
Yakima, Washington, Stati Uniti, 98902
- North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
-
Yelm, Washington, Stati Uniti, 98597
- Providence Regional Cancer System-Yelm
-
-
West Virginia
-
Huntington, West Virginia, Stati Uniti, 25701
- Edwards Comprehensive Cancer Center
-
-
Wisconsin
-
Appleton, Wisconsin, Stati Uniti, 54911
- ThedaCare Regional Cancer Center
-
Ashland, Wisconsin, Stati Uniti, 54806
- Duluth Clinic Ashland
-
Ashland, Wisconsin, Stati Uniti, 54806
- Northwest Wisconsin Cancer Center
-
Berlin, Wisconsin, Stati Uniti, 54923
- ThedaCare Cancer Care - Berlin
-
Burlington, Wisconsin, Stati Uniti, 53105
- Aurora Cancer Care-Southern Lakes VLCC
-
Chippewa Falls, Wisconsin, Stati Uniti, 54729
- Marshfield Clinic-Chippewa Center
-
Cudahy, Wisconsin, Stati Uniti, 53110
- Aurora Saint Luke's South Shore
-
Eau Claire, Wisconsin, Stati Uniti, 54701
- Marshfield Medical Center-EC Cancer Center
-
Germantown, Wisconsin, Stati Uniti, 53022
- Aurora Health Care Germantown Health Center
-
Grafton, Wisconsin, Stati Uniti, 53024
- Aurora Cancer Care-Grafton
-
Green Bay, Wisconsin, Stati Uniti, 54311
- Aurora BayCare Medical Center
-
Hayward, Wisconsin, Stati Uniti, 54843
- Essentia Health-Hayward Clinic
-
Kenosha, Wisconsin, Stati Uniti, 53142
- Aurora Cancer Care-Kenosha South
-
La Crosse, Wisconsin, Stati Uniti, 54601
- Gundersen Lutheran Medical Center
-
Ladysmith, Wisconsin, Stati Uniti, 54848
- Marshfield Medical Center - Ladysmith
-
Marinette, Wisconsin, Stati Uniti, 54143
- Aurora Bay Area Medical Group-Marinette
-
Marshfield, Wisconsin, Stati Uniti, 54449
- Marshfield Medical Center-Marshfield
-
Milwaukee, Wisconsin, Stati Uniti, 53209
- Aurora Cancer Care-Milwaukee
-
Milwaukee, Wisconsin, Stati Uniti, 53215
- Aurora Saint Luke's Medical Center
-
Milwaukee, Wisconsin, Stati Uniti, 53233
- Aurora Sinai Medical Center
-
Minocqua, Wisconsin, Stati Uniti, 54548
- Marshfield Medical Center - Minocqua
-
Mukwonago, Wisconsin, Stati Uniti, 53149
- ProHealth D N Greenwald Center
-
New Richmond, Wisconsin, Stati Uniti, 54017
- Cancer Center of Western Wisconsin
-
Oconomowoc, Wisconsin, Stati Uniti, 53066
- ProHealth Oconomowoc Memorial Hospital
-
Oshkosh, Wisconsin, Stati Uniti, 54904
- Vince Lombardi Cancer Clinic - Oshkosh
-
Racine, Wisconsin, Stati Uniti, 53406
- Aurora Cancer Care-Racine
-
Rice Lake, Wisconsin, Stati Uniti, 54868
- Marshfield Medical Center-Rice Lake
-
Sheboygan, Wisconsin, Stati Uniti, 53081
- Vince Lombardi Cancer Clinic-Sheboygan
-
Spooner, Wisconsin, Stati Uniti, 54801
- Essentia Health-Spooner Clinic
-
Stevens Point, Wisconsin, Stati Uniti, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Summit, Wisconsin, Stati Uniti, 53066
- Aurora Medical Center in Summit
-
Superior, Wisconsin, Stati Uniti, 54880
- Essentia Health Saint Mary's Hospital - Superior
-
Two Rivers, Wisconsin, Stati Uniti, 54241
- Vince Lombardi Cancer Clinic-Two Rivers
-
Waukesha, Wisconsin, Stati Uniti, 53188
- UW Cancer Center at ProHealth Care
-
Waukesha, Wisconsin, Stati Uniti, 53188
- ProHealth Waukesha Memorial Hospital
-
Wausau, Wisconsin, Stati Uniti, 54401
- Marshfield Clinic-Wausau Center
-
Wauwatosa, Wisconsin, Stati Uniti, 53226
- Aurora Cancer Care-Milwaukee West
-
Weston, Wisconsin, Stati Uniti, 54476
- Marshfield Medical Center - Weston
-
Wisconsin Rapids, Wisconsin, Stati Uniti, 54494
- Marshfield Clinic - Wisconsin Rapids Center
-
-
Wyoming
-
Cheyenne, Wyoming, Stati Uniti, 82001
- Cheyenne Regional Medical Center-West
-
Cody, Wyoming, Stati Uniti, 82414
- Billings Clinic-Cody
-
Sheridan, Wyoming, Stati Uniti, 82801
- Welch Cancer Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
RANDOMIZATION (STEP 1): Patient must be >= 18 years of age
-
RANDOMIZATION (STEP 1): Patient must have pathologically confirmed non-squamous non-small cell lung carcinoma (NSCLC). Patients with NSCLC not otherwise specified (NOS) are eligible. Mixed tumors will be categorized by predominant cell type. If small cell elements are present, the patient is ineligible
-
RANDOMIZATION (STEP 1): Patient must have metastatic stage IVA or IVB disease (includes M1a, M1b, and M1c), according to the 8th edition of the lung cancer TNM classification system. Recurrent metastatic NSCLC ineligible for curative therapy (in the treating investigator's opinion) is also allowed
-
RANDOMIZATION (STEP 1): Patient's tumor must be known negative for EGFR tyrosine kinase inhibitor (TKI) sensitizing mutations (for example at a minimum, negative for EGFR Exon 19 deletions, EGFR exon 20 insertions, and Exon 21 L858R, L861Q mutations ) AND negative for ALK gene rearrangements (by fluorescence in situ hybridization [FISH], next generation sequencing [NGS], or immunohistochemistry [IHC]) by routine Clinical Laboratory Improvement Amendments (CLIA)- or Food and Drug Administration (FDA)-certified clinical testing methods. CLIA or FDA approved circulating tumor deoxyribonucleic acid (DNA) testing is acceptable as an alternative to tissue testing
-
RANDOMIZATION (STEP 1): Patient must have radiographic and/or clinical progression (per local investigator assessment) following one, but only one, line of platinum-based chemotherapy AND one, but only one, line of prior checkpoint inhibitor (anti-PD-1 or PD-L1) immunotherapy, either concurrently or sequentially in either order. A minimum of two doses of prior immunotherapy is required. Only one prior line of therapy is allowed if patients received chemotherapy and immunotherapy together (patients may not receive subsequent single agent chemotherapy), and greater than two prior lines of therapy are not allowed.
- NOTE: Lines of therapy are defined by clinical or radiographic progression. For patients with recurrent metastatic NSCLC following treatment for stage 1-3 NSCLC, platinum-based chemotherapy received within 12 months of recurrence and/or immunotherapy received within 6 months of recurrence will meet the requirement for prior chemotherapy and/or immunotherapy but subsequent receipt of more immunotherapy and/or platinum-based chemotherapy is also allowed.
- NOTE: Prior anti-VEGF antibody therapy (ie bevacizumab) is allowed. Prior ipilimumab, or investigational agents not excluded below, in combination with the required prior therapies above are allowed.
- NOTE: Prior receipt of one or two lines of targeted therapy for ROS1, RET, MET, BRAF, ERBB2/HER2, or KRAS G12C positive NSCLC is allowed and will not count toward the line of therapy limit. However, progression is still required after chemotherapy and immunotherapy as above. Patients with ROS1, RET, MET positive NSCLC are strongly encouraged to get appropriate targeted therapy (such as crizotinib, entrectinib, lorlatinib, selpercatinib, pralsetinib, capmatinib, tepotinib, or another investigational, off-label, or approved agent directed against ROS1, RET, or MET positive NSCLC) prior to participation and will be stratified.
- NOTE: No prior predominantly VEGFR directed TKI therapy (such as cabozantinib, lenvatinib, or sitravantinib) is allowed, except for the agents named above.
-
RANDOMIZATION (STEP 1): The investigator must document the intended chemotherapy regimen should their patient be randomized to Arm C (docetaxel and ramucirumab, OR single agent chemotherapy - docetaxel, gemcitabine, paclitaxel, nab-paclitaxel). The patient must not have received the selected chemotherapy agent previously for metastatic disease
-
RANDOMIZATION (STEP 1): Any prior chemotherapy (based on administration schedule) must have been completed in greater than or equal to the following times prior to randomization:
- FDA approved targeted oral therapy must be completed >= 1 week prior
- Chemotherapy and/or immunotherapy must be completed >= 2 weeks prior
- Prior investigational agents must be completed >= 4 weeks prior.
-
RANDOMIZATION (STEP 1): Prior radiation therapy is allowed with a 2 week washout prior to randomization. Patient must not receive any systemic treatment with radionuclides within 6 weeks prior to randomization. Patient must have no clinically relevant ongoing complication from prior radiation therapy
-
RANDOMIZATION (STEP 1): Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen (in the opinion of the treating physician) are eligible for this trial
-
RANDOMIZATION (STEP 1): Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents (such as anthracycline or HER2-directed antibody therapy, but not prior checkpoint inhibitor therapy), must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients must be class 2B or better
-
RANDOMIZATION (STEP 1): Patient must have Eastern Cooperative Oncology Group (ECOG) performance status 0-1
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patient must have met the eligibility criteria outlined above
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patient must have measurable disease as defined by RECIST v1.1. Measurements must be obtained within 4 weeks prior to randomization/registration
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patient must have recovered to equal to or less than grade 1 toxicities related to prior treatment, unless toxicities are clinically non significant and/or stable on supportive therapy (as determined by the treating physician)
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Absolute neutrophil count >= 1,500/mcL (obtained within 2 weeks prior to randomization)
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Platelets >= 100,000/mcL (obtained within 2 weeks prior to randomization)
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Hemoglobin >= 9 g/dL (obtained within 2 weeks prior to randomization)
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (for patients with Gilbert's disease total bilirubin must be =< 3 x ULN) (obtained within 2 weeks prior to randomization)
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x ULN (obtained within 2 weeks prior to randomization)
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Creatinine =< 1.5 x ULN OR calculated (Cockcroft-Gault formula) or measured creatinine clearance >= 50 mL/min/1.73m^2 (normalized to body surface area [BSA]) for patients with creatinine levels greater than 1.5 times the institutional normal creatinine =< 1.5 X ULN or creatinine clearance >= 50ml/min/1.73m^2 (obtained within 2 weeks prior to randomization)
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not be pregnant or breast-feeding due to the unknown effects of cabozantinib and nivolumab on human development and for the potential risk for adverse events in nursing infants with the treatment regimens being used.
- All patients of childbearing potential must have a blood test or urine study within 14 days prior to randomization/registration to rule out pregnancy.
- A patient of childbearing potential is anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study and for 6 months after completion of treatment on the study
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not have clinically significant gastrointestinal bleeding within 6 months prior to randomization
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not have pulmonary hemorrhage or hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood within 3 months prior to randomization
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not have active drug induced pneumonitis within 3 months prior to randomization. Prior immune mediated pneumonitis of grade 3 or 4 are not eligible regardless of time window
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not have current radiographic evidence of tumor invading major blood vessel, evidence of tumor cavitation > 1 cm, evidence of tumor invading the gastrointestinal (GI) tract (esophagus, stomach, small or large bowel, rectum or anus), or evidence of endotracheal or mainstem endobronchial tumor
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not have peptic ulcer disease, known malabsorption syndrome, bowel obstruction or gastric outlet obstruction within 3 months prior to randomization
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not have abdominal fistula, GI perforation, or intra-abdominal abscess within 6 months prior to randomization
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not have grade 3 or greater infection, or infection requiring intravenous systemic treatment within 14 days prior to randomization. Patients must be off antibiotics at the time of randomization
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not have serious non-healing wound/ulcer/bone fracture within 28 days prior to randomization
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not have history of organ transplant
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not have concurrent symptomatic untreated hypothyroidism
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not have history of major surgery within 3 months prior to randomization, minor surgery within 28 days prior to randomization, other minor procedures within 7 days prior to randomization, or clinically relevant ongoing complications from prior procedures
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not have concurrent uncontrolled hypertension defined as sustained blood pressure (BP) > 160 mm Hg systolic, or > 100 mm Hg diastolic despite optimal antihypertensive treatment
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not have unstable angina pectoris, clinically-significant cardiac arrhythmias, stroke (including transient ischemic attack [TIA]), or myocardial infarction within 6 months prior to randomization
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not have a diagnosis of deep vein thrombosis/pulmonary embolism (DVT/PE) within 6 months of randomization unless stable, asymptomatic, and treated with low-molecular-weight heparin (LMWH) or a permitted oral anticoagulant for at least 7 days before randomization
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patient must not be receiving anticoagulants (i.e., warfarin, aspirin, clopidogrel) except:
- Prophylactic use of low-dose aspirin (100 mg po daily or less) and/or low dose molecular weight heparin (LMWH) is permitted.
- Therapeutic doses of low dose molecular weight heparin (LMWH) or specified direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban are allowed in patients without untreated brain metastases who are on a stable dose 7 days prior to study randomization, and without clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patient must not receive strong CYP3A4 inducers (e.g., dexamethasone (> 1 mg daily dosing), phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, and St. John's Wort) within 7 days prior to randomization
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patient must have corrected QT interval calculated by the Fridericia formula (QTcF) =< 500 msec within 28 days prior to Step 1 randomization
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patient must be able to swallow tablets
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patient must not be on continuous systemic treatment with corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 7 days prior to randomization, with the following exceptions:
- Inhaled or topical steroids and adrenal replacement doses =< 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
- Patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption).
- Physiologic replacement doses of systemic corticosteroids are permitted, if < 10 mg/day prednisone equivalents. A brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients with brain metastases are eligible as follows:
- Previously treated brain metastases must have been treated with radiation > 2 weeks prior to randomization or surgery > 3 months prior to randomization OR
- Untreated (active) brain metastases are allowed if they are clinically asymptomatic, < 1 cm, non-hemorrhagic, the patient is not on systemic anticoagulation, and the investigator believes that central nervous system (CNS) specific treatment is unlikely to be required during the first 3 months of study treatment.
- NOTE: Symptomatic leptomeningeal disease is NOT allowed
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patient must not have known active autoimmune disease or known history of autoimmune disease for which recurrence may affect vital organ function or require immune suppressive treatment including systemic corticosteroids (e.g., immune-related neurologic disease, multiple sclerosis, autoimmune neuropathy, Guillain-Barre syndrome, etc.).
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients with known history of human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients with known history of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral at time of randomization (suppressive therapy is allowed, if indicated)
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients with a known history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load at time of randomization
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patient must not have had any prior allergic reaction or hypersensitivity to study drug components or related drugs (multitargeted small molecule tyrosine kinase inhibitors or checkpoint inhibitor monoclonal antibodies)
-
STEP 2 (CROSSOVER ARM Z): Patient must have met all eligibility requirements for Step 1 at time of registration to Step 1 to be eligible for Step 2
-
STEP 2 (CROSSOVER ARM Z): Patient must have radiographic progressive disease per RECIST criteria after >= 2 cycles of therapy on Arm C. The scan showing progression must be completed within 6 weeks prior to Step 2 registration
-
STEP 2 (CROSSOVER ARM Z): Patient must not have intervening anticancer treatment or major surgical procedure(s) between Step 1 and Step 2, except palliative radiation which was completed >= 1 week prior to registration to Step 2
-
STEP 2 (CROSSOVER ARM Z): Patient may not have central nervous system progression, but patients with stable CNS disease are allowed
-
STEP 2 (CROSSOVER ARM Z): Patient must have an ECOG performance status 0-2
-
STEP 2 (CROSSOVER ARM Z): Patient must have recovered to equal to or less than grade 1 toxicities related to prior treatment, unless the adverse event(s) are clinically non significant and/or stable on supportive therapy (as determined by the treating physician)
-
STEP 2 (CROSSOVER ARM Z): Absolute neutrophil count >= 1,500/mcL (obtained within 2 weeks prior to registration to Step 2)
-
STEP 2 (CROSSOVER ARM Z): Platelets >= 100,000/mcL (obtained within 2 weeks prior to registration to Step 2)
-
STEP 2 (CROSSOVER ARM Z): Hemoglobin >= 9 g/dL (obtained within 2 weeks prior to registration to Step 2)
-
STEP 2 (CROSSOVER ARM Z): Total bilirubin =< 1.5 x institutional ULN (for patients with Gilbert's disease total bilirubin must be =< 3 x ULN) (obtained within 2 weeks prior to registration to Step 2)
-
STEP 2 (CROSSOVER ARM Z): AST(SGOT) and ALT(SGPT) =< 2.5 x ULN (obtained within 2 weeks prior to registration to Step 2)
-
STEP 2 (CROSSOVER ARM Z): Creatinine =< 1.5 x ULN OR calculated (Cockcroft-Gault formula) or measured creatinine clearance >= 50 mL/min/1.73m^2 (normalized to BSA) for patients with creatinine levels greater than 1.5 times the institutional normal creatinine =< 1.5 X ULN or creatinine clearance >= 50ml/min/1.73m^2 (obtained within 2 weeks prior to registration to Step 2)
-
STEP 2 (CROSSOVER ARM Z): Patient must have corrected QT interval calculated by the Fridericia formula (QTcF) =< 500 ms within 28 days prior to Step 2 registration
-
STEP 2 (CROSSOVER ARM Z): Patient must not have any intercurrent illness or disease complication that the investigator believes would limit the ability to safely tolerate the combination of cabozantinib and nivolumab
-
STEP 2 (CROSSOVER ARM Z): Patient must not be pregnant or breast-feeding due to the unknown effects of cabozantinib and nivolumab on human development and for the potential risk for adverse events in nursing infants with the treatment regimens being used.
- All patients of childbearing potential must have a blood test or urine study within 14 days prior to registration to Step 2 to rule out pregnancy.
- A patient of childbearing potential is anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
-
STEP 2 (CROSSOVER ARM Z): Patients must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study and for 6 months after completion of treatment on the study
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Step 1, Arm A (cabozantinib S-malate)
Patients in Step 1, Arm A receive cabozantinib S-malate PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may continue to receive therapy after investigator-assessed RECIST 1.1 defined progression, including stable clinical and performance status and have potential for continued clinical benefit. Patients also undergo ECHO as clinically indicated, CT throughout the trial, and collection of blood on study. |
Undergo CT
Altri nomi:
Given PO
Altri nomi:
Undergo ECHO
Altri nomi:
Undergo blood collection
Altri nomi:
|
|
Sperimentale: Step 1, Arm B (cabozantinib S-malate, nivolumab)
Patients in Step 1, Arm B receive cabozantinib S-malate PO QD and nivolumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may continue to receive therapy after investigator-assessed RECIST 1.1 defined progression, including stable clinical and performance status and have potential for continued clinical benefit. Patients also undergo ECHO as clinically indicated, CT throughout the trial, and collection of blood on study. |
Undergo CT
Altri nomi:
Given PO
Altri nomi:
Undergo ECHO
Altri nomi:
Given IV
Altri nomi:
Undergo blood collection
Altri nomi:
|
|
Comparatore attivo: Step 1, Arm C (standard chemotherapy)
Patients in Step 1, Arm C receive ramucirumab IV over 30-60 minutes and docetaxel IV over 1 hour on day 1, or docetaxel IV over 1 hour on days 1 and 8, or gemcitabine hydrochloride IV on days 1 and 8, or paclitaxel IV over 3 hours on day 1, or nab-paclitaxel IV over 30 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity and at the discretion of the treating physician. Patients also undergo ECHO as clinically indicated, CT throughout the trial, and collection of blood on study. |
Given IV
Altri nomi:
Given IV
Altri nomi:
Undergo CT
Altri nomi:
Undergo ECHO
Altri nomi:
Undergo blood collection
Altri nomi:
Given IV
Altri nomi:
Given PO
Altri nomi:
Given IV
Altri nomi:
|
|
Sperimentale: Step 2, Arm Z (cabozantinib S-malate, nivolumab)
Patients in Step 2, Arm Z receive cabozantinib S-malate PO QD and nivolumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may continue to receive therapy after investigator-assessed RECIST 1.1 defined progression, including stable clinical and performance status and have potential for continued clinical benefit. Patients also undergo ECHO as clinically indicated, CT throughout the trial, and collection of blood on study. |
Undergo CT
Altri nomi:
Given PO
Altri nomi:
Undergo ECHO
Altri nomi:
Given IV
Altri nomi:
Undergo blood collection
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Progression-free survival (PFS) for patient population with non-squamous no-small cell lung cancer (NSCLC)
Lasso di tempo: After 58 events (From time of randomization to documented disease progression [site review of imaging] or death from any cause, whichever occurs first)
|
The final analysis of PFS will be performed when the full information of PFS is reached (i.e., 58 events for each of the two primary comparisons). The two primary comparisons of PFS will each use a logrank test stratified on the randomization stratification factors with a one-sided type I error rate of 10%. Estimates of PFS including medians and confidence intervals, will be calculated using the Kaplan-Meier method. Cox proportional hazards models, stratified, on the same factors, will be used to estimate the treatment hazard ratios. At the final analyses, in the event that both primary PFS comparisons of the combination of nivolumab with cabozantinib and cabozantinib alone versus the standard chemotherapy are statistically significant, PFS will be compared between the two experimental arms (combination of nivolumab with cabozantinib versus [vs.] cabozantinib alone), using a stratified log rank test with a one-sided type I error rate of 10%. |
After 58 events (From time of randomization to documented disease progression [site review of imaging] or death from any cause, whichever occurs first)
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Overall survival (OS) for each arm
Lasso di tempo: From time of randomization to documented disease progression (site review of imaging) or death from any cause, whichever occurs first, assessed up to 3 years
|
The final analysis of OS will be performed when the full information of PFS is reached (i.e., 58 events for each of the two primary comparisons). OS will be tested in a hierarchical fashion if the primary comparison of PFS between treatment arms is statistically significant, using a log rank test stratified on the randomization stratification factors with a one-sided type I error rate of 10%. Estimates of OS, including medians and confidence intervals, will be calculated using the Kaplan-Meier method. Cox proportional hazards models, stratified, on the same factors, will be used to estimate the treatment hazard ratios. OS will be further tested in a hierarchical fashion if the comparison of PFS between the two experimental arms is statistically significant. Point estimates of all endpoints will be accompanied by the corresponding two-sided 80% confidence intervals. Subset analyses of PFS and OS by treatment arm will be estimated and compared within subsets. |
From time of randomization to documented disease progression (site review of imaging) or death from any cause, whichever occurs first, assessed up to 3 years
|
|
Best objective response for each arm
Lasso di tempo: Every 6 weeks for the first year on study, and then every 12 weeks after year one
|
Will be evaluated via Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Response rates (complete response [CR] + partial response [PR]) and toxicity will be compared using Fisher's exact tests with a one-sided type I error rate of 10%; multivariable logistic regression modeling will be used to adjust for the effect of any covariates that are associated with these categorical outcomes. Modeling procedures will implement backward selection; variables significant at the 0.10 level in the univariate setting will be chosen for inclusion in an initial full model, and at each step the least significant variable will be removed from the model. Only those covariates with p < 0.05 will remain in any final models, unless there are factors identified by the study team as crucial to model interpretation. Point estimates of all endpoints will be accompanied by the corresponding two-sided 80% confidence intervals. |
Every 6 weeks for the first year on study, and then every 12 weeks after year one
|
|
Toxicity profile of monotherapy with cabozantinib, and the combination of nivolumab and cabozantinib
Lasso di tempo: Up to 3 years after completion of study treatment
|
Will be determined using the Common Terminology Criteria for Adverse Events (CTCAE) criteria. Response rates (complete response [CR] + pathologic response [PR]) and toxicity will be compared using Fisher's exact tests with a one-sided type I error rate of 10%; multivariable logistic regression modeling will be used to adjust for the effect of any covariates that are associated with these categorical outcomes. Modeling procedures will implement backward selection; variables significant at the 0.10 level in the univariate setting will be chosen for inclusion in an initial full model, and at each step the least significant variable will be removed from the model. Only those covariates with p < 0.05 will remain in any final models, unless there are factors identified by the study team as crucial to model interpretation. Point estimates of all endpoints will be accompanied by the corresponding two-sided 80% confidence intervals. |
Up to 3 years after completion of study treatment
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
The RECIST1.1 response at each time point
Lasso di tempo: Every 6 weeks for the first year on study, and then every 12 weeks after year one
|
The measurement of each time point will be performed using the revised CHOI criteria will be only applied to arms A and B, which will include anti-angiogenic therapy. Both the RECIST1.1 and revised CHOI criteria will assess the overall best response as CR, partial PR, stable disease (SD), or progressive disease (PD). Their concordance will be assessed using the weighted Cohen's kappa coefficient (k) with quadratic weights. As a rule of thumb, the level of concordance between the two criteria will be considered poor (k <0), slight (k 0-0.20), fair (k 0.21-0.40), moderate (k 0.41-0.60), substantial (k 0.61-0.80), and almost perfect (k 0.81 - 1). |
Every 6 weeks for the first year on study, and then every 12 weeks after year one
|
|
Agreement between central view and site review in terms of progression-free survival
Lasso di tempo: After the completion of study treatment
|
The progression status and the progression time will be assessed in agreement. The progression status is a binary measurement and the agreement will be assessed using the Cohen's kappa coefficient. For progression time, will assess the temporal agreement using the method developed by Zeng et al. |
After the completion of study treatment
|
|
Correlative biomarker research
Lasso di tempo: After the completion of study treatment
|
Correlative biomarker research will be performed on tissue and blood specimens collected within this trial. |
After the completion of study treatment
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Joel W Neal, ECOG-ACRIN Cancer Research Group
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Neoplasie per sede
- Neoplasie
- Malattie delle vie respiratorie
- Malattie polmonari
- Neoplasie delle vie respiratorie
- Neoplasie toraciche
- Neoplasie polmonari
- Aminoacidi, peptidi e proteine
- Proteine
- Prodotti chimici organici
- Composti eterociclici, 1-anello
- Composti eterociclici
- Tecniche investigative
- Tecniche di laboratorio clinico
- Tecniche e procedure diagnostiche
- Diagnosi
- Idrocarburi
- Cicloparaffins
- Idrocarburi, aliciclici
- Idrocarburi, ciclici
- Terpeni
- Anticorpi, monoclonali, umanizzati
- Anticorpi, monoclonali
- Anticorpi
- Immunoglobuline
- Immunoproteine
- Proteine del sangue
- Globuline sieriche
- Globuline
- Taxoidi
- Ciclodecani
- Diterpenes
- Deossictidina
- Citidina
- Nucleosidi di pirimidina
- Pirimidine
- Economia e organizzazioni sanitarie
- Albumine
- Economia
- Docetaxel
- Nivolumab
- Paclitaxel legato all'albumina
- Gemcitabina
- Ramucirumab
- Paclitaxel
- Gestione dei campioni
- Paclitaxel diretto da 130 nm su albumina
- Cabozantinib
- Tasse
Altri numeri di identificazione dello studio
- NCI-2020-01541
- U10CA180820 (Sovvenzione/contratto NIH degli Stati Uniti)
- NCI-2020-01541 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
- EA5191 (Altro identificatore: CTEP)
- EA5191 (Altro identificatore: ECOG-ACRIN Cancer Research Group)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .